Millennium Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Millennium Management’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$339K	Buy	103,470 +42,093	+69%	+$244K	﹤0.01%	4954
2025 Q4	$460K	Sell	61,377 -11,914	-16%	-$67.2K	﹤0.01%	4998
2025 Q3	$243K	Buy	73,291 +55,781	+319%	+$157K	﹤0.01%	5454
2025 Q2	$52.9K	Buy	17,510 +4,106	+31%	+$12.4K	﹤0.01%	5609
2025 Q1	$41K	Buy	+13,404	New	+$36.2K	﹤0.01%	5562
2023 Q4	–	Sell	-14,754	Closed	-$48.4K	–	6396
2023 Q3	$48.4K	Sell	14,754 -2,134	-13%	-$7.94K	﹤0.01%	5482
2023 Q2	$77.7K	Sell	16,888 -6,848	-29%	-$34.5K	﹤0.01%	5383
2023 Q1	$168K	Sell	23,736 -4,332	-15%	-$32.2K	﹤0.01%	5243
2022 Q4	$180K	Sell	28,068 -8,001	-22%	-$88.2K	﹤0.01%	5372
2022 Q3	$527K	Sell	36,069 -13,739	-28%	-$238K	﹤0.01%	4932
2022 Q2	$896K	Buy	+49,808	New	+$1.13M	﹤0.01%	4468
2022 Q1	–	Sell	-7,053	Closed	-$306K	–	7315
2021 Q4	$306K	Sell	7,053 -7,906	-53%	-$455K	﹤0.01%	5520
2021 Q3	$1.06M	Sell	14,959 -11,819	-44%	-$1.09M	﹤0.01%	4604
2021 Q2	$3.07M	Sell	26,778 -2,461	-8%	-$240K	﹤0.01%	3403
2021 Q1	$3.04M	Buy	29,239 +26,352	+913%	+$2.5M	﹤0.01%	3123
2020 Q4	$138K	Buy	2,887 +870	+43%	+$31.9K	﹤0.01%	4960
2020 Q3	$56	Buy	+2,017	New	+$57.8K	﹤0.01%	4288
2019 Q4	–	Sell	-2,503	Closed	-$105K	–	4513
2019 Q3	$105K	Sell	2,503 -1,959	-44%	-$77K	﹤0.01%	3958
2019 Q2	$222K	Sell	4,462 -6,965	-61%	-$579K	﹤0.01%	3705
2019 Q1	$903K	Buy	+11,427	New	+$737K	﹤0.01%	2923
2018 Q4	–	Sell	-1,579	Closed	-$79K	–	4055
2018 Q3	$79K	Sell	1,579 -4,612	-74%	-$238K	﹤0.01%	3762
2018 Q2	$316K	Buy	+6,191	New	+$305K	﹤0.01%	3367
2017 Q2	–	Sell	-1,317	Closed	-$157K	–	3740
2017 Q1	$157K	Buy	+1,317	New	+$152K	﹤0.01%	3272
2016 Q2	–	Sell	-536	Closed	-$49K	–	3444
2016 Q1	$49K	Buy	+536	New	+$47.5K	﹤0.01%	3153

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HCM

Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Millennium Management's IMDX Position: Q1 2026 in Review

Millennium Management increased its Insight Molecular Diagnostics (IMDX) stake by 69% in Q1 2026, buying an estimated $244K and bringing the position to 103,470 shares worth $339K. The position accounts for ﹤0.01% of the portfolio, ranked #4954.

Millennium Management first reported a position in IMDX in Q1 2016 and has held it in 24 quarters since. The position peaked at $3.07M in Q2 2021. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

Millennium Management held 103,470 shares of Insight Molecular Diagnostics worth $339K as of Q1 2026.
Millennium Management bought 42,093 Insight Molecular Diagnostics shares in Q1 2026, an estimated $244K.
Insight Molecular Diagnostics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #4954 holding.
Millennium Management first reported a position in Insight Molecular Diagnostics in Q1 2016 and has held it in 24 quarters since.
Millennium Management's Insight Molecular Diagnostics position peaked at $3.07M in Q2 2021.
41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.